This inventor holds 5 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Oregon Health & Science University. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: The Innovative Contributions of Daniel Malouli
Introduction
Daniel Malouli is a prominent inventor based in Hillsboro, Oregon. He has made significant contributions to the field of immunology, particularly in the development of cytomegalovirus (CMV) vectors. With a total of 5 patents to his name, Malouli's work has the potential to advance therapeutic strategies for various diseases.
Latest Patents
Malouli's latest patents focus on CMV vectors that elicit T cell responses restricted by major histocompatibility complex E molecules. One of his notable inventions includes CMV vectors that lack active UL128, UL130, UL146, and UL147 proteins, which may also incorporate microRNA regulatory elements. These vectors allow for the selection of different CD8+ T cell responses, including those restricted by MHC-Ia, MHC-II, or MHC-E. Additionally, he has developed methods for inducing CD8+ T cell responses to heterologous antigens, ensuring that at least 10% of the CD8+ T cells are MHC-E restricted.
Career Highlights
Malouli is affiliated with Oregon Health & Science University, where he conducts his research and develops innovative solutions in immunology. His work has garnered attention for its potential applications in vaccine development and cancer therapy.
Collaborations
Throughout his career, Malouli has collaborated with esteemed colleagues such as Louis Picker and Scott G. Hansen. These partnerships have further enriched his research and contributed to the advancement of immunological studies.
Conclusion
Daniel Malouli's innovative work in the field of immunology, particularly with CMV vectors, showcases his dedication to advancing medical science. His contributions are paving the way for new therapeutic approaches that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile